172 related articles for article (PubMed ID: 20562403)
1. Delayed onset of a second paraneoplastic neurological syndrome in eight patients.
Ducray F; Graus F; Vigliani MC; Antoine JC; Rogemond V; Saiz A; Honnorat J
J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):937-9. PubMed ID: 20562403
[TBL] [Abstract][Full Text] [Related]
2. "Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected.
Berger B; Bischler P; Dersch R; Hottenrott T; Rauer S; Stich O
J Neurol Sci; 2015 May; 352(1-2):58-61. PubMed ID: 25824848
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.
Storstein A; Raspotnig M; Vitaliani R; Giometto B; Graus F; Grisold W; Honnorat J; Vedeler CA
J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485
[TBL] [Abstract][Full Text] [Related]
5. Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies.
Raspotnig M; Vedeler C; Storstein A
J Neurol Sci; 2015 Jan; 348(1-2):41-5. PubMed ID: 25467140
[TBL] [Abstract][Full Text] [Related]
6. Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome.
Vogrig A; Joubert B; Maureille A; Thomas L; Bernard E; Streichenberger N; Cotton F; Ducray F; Honnorat J
J Neurol; 2019 Feb; 266(2):398-410. PubMed ID: 30498914
[TBL] [Abstract][Full Text] [Related]
7. Paraneoplastic neurological syndromes with onconeural antibodies: A single center retrospective study.
Oliveira V; Videira G; Samões R; Carneiro P; Neves E; Santos E
J Neurol Sci; 2020 Nov; 418():117103. PubMed ID: 32877801
[TBL] [Abstract][Full Text] [Related]
8. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.
Honnorat J; Cartalat-Carel S; Ricard D; Camdessanche JP; Carpentier AF; Rogemond V; Chapuis F; Aguera M; Decullier E; Duchemin AM; Graus F; Antoine JC
J Neurol Neurosurg Psychiatry; 2009 Apr; 80(4):412-6. PubMed ID: 18931014
[TBL] [Abstract][Full Text] [Related]
9. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.
Ariño H; Höftberger R; Gresa-Arribas N; Martínez-Hernández E; Armangue T; Kruer MC; Arpa J; Domingo J; Rojc B; Bataller L; Saiz A; Dalmau J; Graus F
JAMA Neurol; 2015 Aug; 72(8):874-81. PubMed ID: 26099072
[TBL] [Abstract][Full Text] [Related]
10. A single center retrospective study of paraneoplastic neurological syndromes with positive onconeural antibodies.
Fu P; He L; Tang N; Nie Q; Li Z
J Clin Neurosci; 2021 Jul; 89():336-342. PubMed ID: 34119290
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypical characterization of paraneoplastic neurological syndrome patients: a multicentric study.
Lorusso L; Precone V; Hart IK; Giometto B; Pezzani R; Ngonga GK; Ngonga GKNK; Paolacci S; Ferrari D; Ricevuti G; Marshall E; Bertelli M
J Biosci; 2021; 46():. PubMed ID: 33709965
[TBL] [Abstract][Full Text] [Related]
12. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes.
Stich O; Klages E; Bischler P; Jarius S; Rasiah C; Voltz R; Rauer S
Acta Neurol Scand; 2012 May; 125(5):326-31. PubMed ID: 21751968
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic antibody during follow-up of a patient with anti-Ri-associated paraneoplastic neurological syndrome.
Stich O; Rasiah C; Rauer S
Acta Neurol Scand; 2009 May; 119(5):338-40. PubMed ID: 18822086
[TBL] [Abstract][Full Text] [Related]
14. Imbalance in circulating T lymphocyte subsets contributes to Hu antibody-associated paraneoplastic neurological syndromes.
Zhang L; Qian W; Chen Q; Yin L; Li B; Wang H
Cell Immunol; 2014 Aug; 290(2):245-50. PubMed ID: 25173445
[TBL] [Abstract][Full Text] [Related]
15. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases.
Hoffmann LA; Jarius S; Pellkofer HL; Schueller M; Krumbholz M; Koenig F; Johannis W; la Fougere C; Newman T; Vincent A; Voltz R
J Neurol Neurosurg Psychiatry; 2008 Jul; 79(7):767-73. PubMed ID: 18223018
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid study in paraneoplastic syndromes.
Psimaras D; Carpentier AF; Rossi C;
J Neurol Neurosurg Psychiatry; 2010 Jan; 81(1):42-5. PubMed ID: 19324868
[TBL] [Abstract][Full Text] [Related]
17. Neurological paraneoplastic syndromes in lung cancer patients.
Stefens-Stawna P; Piorunek T; Gabryel-Batura H; Kozubski W; Michalak S
Adv Exp Med Biol; 2013; 756():333-9. PubMed ID: 22836651
[TBL] [Abstract][Full Text] [Related]
18. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers.
Giometto B; Grisold W; Vitaliani R; Graus F; Honnorat J; Bertolini G;
Arch Neurol; 2010 Mar; 67(3):330-5. PubMed ID: 20212230
[TBL] [Abstract][Full Text] [Related]
19. Quantification of circulating anti-Hu antibody in serial samples from patients with paraneoplastic neurological syndromes: possible correlation of antibody concentration and course of neurological symptoms.
Rauer S; Czygan M; Kaiser R
J Neurol; 2002 Mar; 249(3):285-9. PubMed ID: 11993527
[TBL] [Abstract][Full Text] [Related]
20. Onconeural antibodies in patients with neurological symptoms: detection and clinical significance.
Raspotnig M; Vedeler CA; Storstein A
Acta Neurol Scand Suppl; 2011; (191):83-8. PubMed ID: 21711262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
